ReviewFrontiers in cardiovascular medicine2023
Molecular and cellular mechanisms of inflammation in atherosclerosis.
Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 53 citations in OpenAlex.
- Ilexoside K Ameliorates Atherosclerosis by Suppressing CD72Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Antioxidants in Oxidative Stress and Obesity-Associated Diseases: Molecular Mechanisms and Potential Health Implications.Biomedicines · 2026Review
- Microbial mechanisms in atherosclerosis: Revisiting the infectious hypothesis.Atherosclerosis plus · 2026Review
- Residual Inflammatory Potential in Patients with Treated Non-Definite and Definite Familial Hypercholesterolaemia: A Clinical Study.Journal of personalized medicine · 2026Article
- Endothelial cells modulate immune cell responses during atherosclerosis.Trends in immunology · 2026Review
- Immunothrombotic Cell-Cell Communication Networks in Coronary Atherosclerosis: Critical Insights from Single-Cell and Spatial Systems Biology.International journal of molecular sciences · 2026Review
- Cell type-specific epigenetic regulatory circuitry of coronary artery disease loci.Nature communications · 2026Article
- Comparative value of novel inflammatory indices in predicting incident carotid atherosclerosis: SIRI outperforms other markers in a general population.Frontiers in cardiovascular medicine · 2026Article
- Associations Between Systemic Inflammatory Markers, Metabolic Dysfunction, and Liver Fibrosis Scores in Patients with MASLD.Metabolites · 2025Article
- miRNAs from mesenchymal-stem-cell-derived extracellular vesicles: Emerging players in regenerative medicine and disease therapy.Molecular therapy. Nucleic acids · 2025Review
- Engineered immune-driven theranostics for clinical cardiology.Military Medical Research · 2025Review
- Polymer-Based Scaffolds Incorporating Selected Essential Oil Components for Wound Healing: A Review.Pharmaceutics · 2025Review
- Probiotic Supplementation and Inflammatory Status in Coronary Artery Disease: A Systematic Review and Meta-Analysis.Microorganisms · 2025Review
- The triglyceride-glucose index: updating evidence from clinical settings to molecular mechanisms in ageing-related cerebrovascular diseases.Cardiovascular diabetology · 2025Review
- Multi-omics to evaluate the protective mechanisms during Akkermansia muciniphila treatment of Candida albicans colonization and subsequent infection.Journal of microbiology (Seoul, Korea) · 2025Article
- S100a8 and s100a9 are elevated in aortic wall from patients with moderate-and-severe obstructive sleep apnea syndrome.Sleep & breathing = Schlaf & Atmung · 2025Article
- A Clinical Retrospective Study on the Combined Use of Monocyte-to-Lymphocyte Ratio and Triglyceride-Glucose Index to Predict the Severity of Coronary Artery Disease.Cardiology research · 2025Article
- Systemic immune-inflammation index and long-term mortality in patients with hypertension: a cohort study.Journal of hypertension · 2025Article
- The Anti-Inflammatory Potential of Tricyclic Antidepressants (TCAs): A Novel Therapeutic Approach to Atherosclerosis Pathophysiology.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Inflammatory Pathways in Coronary Artery Disease: Which Ones to Target for Secondary Prevention?Cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis and its complications are a major cause of morbidity and mortality worldwide in spite of the improved medical and invasive treatment in terms of revascularization. Atherosclerosis is a dynamic, multi-step process in which inflammation is a ubiquitous component participating in the initiation, development, and entanglements of the atherosclerotic plaque. After activation, the immune system, either native or acquired, is part of the atherosclerotic dynamics enhancing the pro-atherogenic function of immune or non-immune cells, such as endothelial cells, smooth muscle cells, or platelets, through mediators such as cytokines or directly by cell-to-cell interaction. Cytokines are molecules secreted by the activated cells mentioned above that mediate the inflammatory component of atherosclerosis whose function is to stimulate the immune cells and the production of further cytokines. This review provides insights of the cell axis activation and specific mechanisms and pathways through which inflammation actuates atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.